Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 651.

https://doi.org/10.1182/blood-2025-651

Published: 2025

Journal Articles

Pivekimab sunirinine (PVEK) combined with FLAG-IDA for medically fit adults with untreated adverse-risk Acute Myeloid Leukemia (AML) or other high-grade myeloid neoplasms (NCT06034470)

Jacob Appelbaum, Suravi Raychaudhuri, Katie Russell, Kimberly Cadiz, Stacey Fuller, Anna Halpern, Cristina Maria Ghiuzeli, Raya Mawad, Vivian Oehler, Ryan Cassaday, Jason Cooper, Paul Hendrie, Megan Othus, Mary-Elizabeth Percival, Roland Walter

Blood (2025) 146 (Supplement 1): 3422.

https://doi.org/10.1182/blood-2025-3422

Published: 2025

Journal Articles

Impact of anti-thymocyte globulin on graft-versus-host disease risk among HLA-matched related donors undergoing allogeneic hematopoietic cell transplantation for aplastic anemia

Daniel Olivieri, Ted Gooley, Shivaprasad Manjappa, Roland Walter, Sioban Keel, Rainer Storb, Phuong Vo

Blood (2025) 146 (Supplement 1): 6005.

https://doi.org/10.1182/blood-2025-6005

Published: 2025

Journal Articles

Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the cadenza study

Naveen Pemmaraju, Luca Mazzarella, Giovanni Marconi, David Sallman, Matthew Ulrickson, Roland Walter, Valerio Maisano, Breanne Fishman, Yining Du, Jalaja Potluri, Hagop Kantarjian, Naval Daver

Blood (2025) 146 (Supplement 1): 5195.

https://doi.org/10.1182/blood-2025-5195

Published: 2025

Journal Articles

Clinical impact of delays in insurance authorization for newly diagnosed Acute Myeloid Leukemia considered for intensive induction chemotherapy

Daniel Olivieri, Fazal Yakub, Gurbani Kaur, Chris Davis, Ryan Basom, Roland Walter, Anna Halpern

Blood (2025) 146 (Supplement 1): 4426.

https://doi.org/10.1182/blood-2025-4426

Published: 2025

Journal Articles

Fractionated gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) based induction chemotherapy is safe and highly effective for newly diagnosed favorable risk AML.

Brenda Castillo, Jacob Appelbaum, Megan Othus, Katie Russell, Rutu Vyas, Paul Hendrie, Anna Halpern, Cristina Maria Ghiuzeli, Ryan Cassaday, Raya Mawad, Mary-Elizabeth Percival, Roland Walter

Blood (2025) 146 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2025-3378

Published: 2025

Journal Articles

Clinical features and outcomes of acquired versus baseline TP53 mutations in myeloid neoplasms: A single-center retrospective analysis

Jason Gilbert, Megan Othus, Suravi Raychaudhuri, Katie Russell, Carole Shaw, Rutu Vyas, Anna Halpern, Paul Hendrie, Raya Mawad, Cristina Maria Ghiuzeli, Ryan Cassaday, Roland Walter, Jacob Appelbaum, Mary-Elizabeth Percival

Blood (2025) 146 (Supplement 1): 7022.

https://doi.org/10.1182/blood-2025-7022

Published: 2025

Journal Articles

Type and degree/number of immunophenotypic abnormalities refine multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) testing in adults allografted for Acute Myeloid Leukemia (AML) in morphologic remission

Calvin Le, Xueyan Chen, Shunya Kodaira, Othus Megan, Chris Davis, Ryan Basom, Sindhu Cherian, Roland Walter

Blood (2025) 146 (Supplement 1): 3519.

https://doi.org/10.1182/blood-2025-3519

Published: 2025

Journal Articles

Treatment intensity and transplant independently predict survival in TP53-mutated myeloid neoplasms: A large retrospective cohort study of clinical and genomic factors

Sarah Peterson, Megan Othus, Katie Russell, Carole Shaw, Rutu Vyas, Anna Halpern, Cristina Maria Ghiuzeli, Paul Hendrie, Ryan Cassaday, Raya Mawad, Roland Walter, Jacob Appelbaum, Mary-Elizabeth Percival

Blood (2025) 146 (Supplement 1): 5265.

https://doi.org/10.1182/blood-2025-5265

Published: 2025

Journal Articles

Interim results of a quality improvement study evaluating subjective and objective sleep quality in hospitalized adults with acute leukemia

Michelle Zhang, Katie Russell, Madison Frieler, Kate Ramsower, Alexi Vasbinder, Roland Walter, Anna Halpern

Blood (2025) 146 (Supplement 1): 7956.

https://doi.org/10.1182/blood-2025-7956

Published: 2025

Journal Articles

Association of CD34+ cell dose on outcome after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation (PBSCT) for adults with Acute Myeloid Leukemia (AML) in measurable residual disease (MRD)-negative remission

Margery Gang, Megan Othus, Anne-Chloe Olix, Fazal Yakub, Gurbani Kaur, Chris Davis, Ryan Basom, Kate Markey, Derek Stirewalt, Laura Connelly-Smith, Filippo Milano, Roland Walter

Blood (2025) 146 (Supplement 1): 2481.

https://doi.org/10.1182/blood-2025-2481

Published: 2025

Journal Articles

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial

Mitin Nachu, Philip Stevenson, Kim Quach, Christen Martino, Mary-Elizabeth Percival, Anna Halpern, Pamela Becker, Vivian Oehler, Jason P. Cooper, Johnnie Orozco, Paul Hendrie, Roland Walter, Cristina Maria Ghiuzeli, Raya Mawad, Ryan Cassaday

Blood (2025) 146 (Supplement 1): 5128.

https://doi.org/10.1182/blood-2025-5128

Published: 2025

Journal Articles

Role of DNA damage sensing and TP53 function as modulators of sensitivity to calicheamicin-based antibody-drug conjugates (ADCs) for acute leukemia

Camryn Pettenger-Willey, George Laszlo, Frances Cole, Colin Godwin, Sarah Erraiss, Pritha Chanana, Allie Kehret, Eduardo Rodríguez-Arbolí, David Wu, Junyang Li, Margery Gang, Jacob Barton, Meghann Yochim, Roland Walter

Blood (2025) 146 (Supplement 1): 6811.

https://doi.org/10.1182/blood-2025-6811

Published: 2025

Journal Articles

Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms: A single-center retrospective analysis

Blood (2025) 146 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2025-1677

Published: 2025

Journal Articles

A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms

Anna Halpern, Megan Othus, Mary-Elizabeth Percival, Cristina Maria Ghiuzeli, Jacob Appelbaum, Paul Hendrie, Ryan Cassaday, Bart Scott, Jason Cooper, Sioban Keel, Vivian Oehler, Johnnie Orozco, Katie Russell, Raya Mawad, Roland Walter

Blood (2025) 146 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2025-1663

Published: 2025

Journal Articles

HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling

Roland Walter, Kuan-Ting Pan, Carmen Doebele, Federico Comoglio, Katarzyna Tomska, Hanibal Bohnenberger, Ryan M. Young, Laura Jacobs, Ulrich Keller, Halvard Bönig, Michael Engelke, Andreas Rosenwald, Henning Urlaub, Louis M. Staudt, Hubert Serve, Thorsten Zenz, Thomas Oellerich

Blood (2017) 129 (5): 598–608.

https://doi.org/10.1182/blood-2016-06-721423

Published: 2017

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

Pivekimab sunirinine (PVEK) combined with FLAG-IDA for medically fit adults with untreated adverse-risk Acute Myeloid Leukemia (AML) or other high-grade myeloid neoplasms (NCT06034470)

Impact of anti-thymocyte globulin on graft-versus-host disease risk among HLA-matched related donors undergoing allogeneic hematopoietic cell transplantation for aplastic anemia

Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the cadenza study

Clinical impact of delays in insurance authorization for newly diagnosed Acute Myeloid Leukemia considered for intensive induction chemotherapy

Fractionated gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) based induction chemotherapy is safe and highly effective for newly diagnosed favorable risk AML.

Clinical features and outcomes of acquired versus baseline TP53 mutations in myeloid neoplasms: A single-center retrospective analysis

Type and degree/number of immunophenotypic abnormalities refine multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) testing in adults allografted for Acute Myeloid Leukemia (AML) in morphologic remission

Treatment intensity and transplant independently predict survival in TP53-mutated myeloid neoplasms: A large retrospective cohort study of clinical and genomic factors

Interim results of a quality improvement study evaluating subjective and objective sleep quality in hospitalized adults with acute leukemia

Association of CD34+ cell dose on outcome after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation (PBSCT) for adults with Acute Myeloid Leukemia (AML) in measurable residual disease (MRD)-negative remission

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial

Role of DNA damage sensing and TP53 function as modulators of sensitivity to calicheamicin-based antibody-drug conjugates (ADCs) for acute leukemia

Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms: A single-center retrospective analysis

A randomized phase 2 trial of CPX-351 vs. CLAG-m (Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone) in medically less-fit adults with previously untreated acute myeloid leukemia (AML) or other high-grade myeloid neoplasms

HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only